Cargando…
A quest for therapeutic antigens in bone and soft tissue sarcoma
Over the past three decades, there have been remarkable advances in the treatment of bone and soft tissue sarcomas. These include the introduction of adjuvant chemotherapy, establishment of guidelines for adequate surgical margins, and the development of post-excision reconstruction. There have also...
Autores principales: | Kawaguchi, Satoshi, Wada, Takuro, Tsukahara, Tomohide, Ida, Kazunori, Torigoe, Toshihiko, Sato, Noriyuki, Yamashita, Toshihiko |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1188080/ https://www.ncbi.nlm.nih.gov/pubmed/16086842 http://dx.doi.org/10.1186/1479-5876-3-31 |
Ejemplares similares
-
HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor
por: Tsukahara, Tomohide, et al.
Publicado: (2009) -
Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma
por: Kawaguchi, Satoshi, et al.
Publicado: (2005) -
High Expression of CD109 Antigen Regulates the Phenotype of Cancer Stem-Like Cells/Cancer-Initiating Cells in the Novel Epithelioid Sarcoma Cell Line ESX and Is Related to Poor Prognosis of Soft Tissue Sarcoma
por: Emori, Makoto, et al.
Publicado: (2013) -
Implication of chemo‐resistant memory T cells for immune surveillance in patients with sarcoma receiving chemotherapy
por: Shibayama, Yuji, et al.
Publicado: (2017) -
Identification of novel human leukocyte antigen‐A*11:01‐restricted cytotoxic T‐lymphocyte epitopes derived from osteosarcoma antigen papillomavirus binding factor
por: Li, Dongliang, et al.
Publicado: (2019)